ClinicalTrials.gg
TerminatedNCT04024813Updated Jan 16, 2025Results posted

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

A Phase 2 interventional study of Seladelpar and Placebo to match Seladelpar in Primary Sclerosing Cholangitis, sponsored by Gilead Sciences. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
53rd of 57
1 · median 27
Started
2019
with 4 others
Phase 2
26 of 75
6 open now
Registered
49th of 75
by date
Lead sponsor
7 of 75
Gilead Sciences

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 53rd largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2019, is one of 26 in phase 2, and was the 49th registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 39 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).

03

Conditions studied

  • Primary Sclerosing Cholangitis

Keywords

  • PSC
  • Cholangitis, Sclerosing
  • Cholangitis
  • Bile Duct Diseases
  • Biliary Tract Diseases
  • Digestive System Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Confirmed diagnosis of primary sclerosing cholangitis (PSC) based on any two of the following three criteria:

    • Historical evidence of an elevated alkaline phosphatase (AP) > (ULN) from any prior laboratory result
    • Liver consistent with PSC
    • Abnormal cholangiography consistent with PSC as measured by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous transhepatic cholangiography (PTC)
  2. Individuals must have the following specific additional laboratory parameters measured by the Central Laboratory at Screening:

    • AP ≥ 1.5 × ULN and \< 8 × ULN
    • Total ≤ 2 × ULN
    • (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN
    • Estimated (eGFR) > 60 mL/min/1.73 m\^2
    • ≥ 140 × 10\^3/µL
    • (INR) ≤ 1.3 (in the absence of warfarin or other anticoagulant therapy)
    • Albumin ≥ 3.5 g/dL
  3. Patients taking ursodeoxycholic acid (UDCA) will be allowed to enroll if meeting the following criteria:

    • Total daily dose of ≤ 20 mg/kg/day
    • A minimum of 6 months of stable treatment
    • Minimum of 12 weeks off treatment prior to Screening if UDCA is recently discontinued

Key Exclusion Criteria:

  1. acute or chronic liver disease of an etiology other than PSC
  2. Patients with a diagnosis of overlapping hepatitis (AIH) and PSC
  3. Secondary or immunoglobulin G4 (IgG4) related sclerosing cholangitis
  4. Small duct PSC
  5. Presence of a cholangiocarcinoma on cholangiography or MRI at Screening as determined by the central radiologist and the principal investigator (PI) or medical monitor
  6. Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation procedure of a stricture within 12 weeks of Screening
  7. History, evidence, or high suspicion of cholangiocarcinoma or other hepatobiliary based on imaging, screening laboratory values, and/or clinical symptoms
  8. Presumptive or diagnosed acute cholangitis within 12 weeks of Screening and through Day 1
  9. Evidence of compensated or decompensated cirrhosis based on histology, relevant medical complications, or laboratory parameters:

    • Historical liver biopsy demonstrating cirrhosis (eg, Ludwig Stage 4 or Ishak Stage 5)
    • Current or prior history of decompensated liver disease, including ascites, hepatic encephalopathy, variceal bleeding or other clinical conditions consistent with cirrhosis and/or portal hypertension,
    • Liver stiffness > 14.4 kPa by FibroScan, or
    • Combined low platelet count (\< 140 × 10\^3/µL ) with one of the following:

      • Serum albumin \< 3.5 g/dL,
      • INR > 1.3 (not due to antithrombotic agent use), or
      • Total bilirubin > ULN
  10. Prior or actively listed for liver transplantation
  11. Prior exposure to seladelpar

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Placebo comparator
    Placebo (N=25)

    Placebo for the remainder of the study

    Drug: Placebo to match Seladelpar

  • Experimental
    Seladelpar 5 mg (N=25)

    5 mg seladelpar daily for the remainder of the study

    Drug: Seladelpar

  • Experimental
    Seladelpar 10 mg (N=25)

    10 mg seladelpar for the remainder of the study

    Drug: Seladelpar

  • Experimental
    Seladepar 25 mg (N=25)

    25 mg seladelpar for the remainder of the study

    Drug: Seladelpar

Interventions

  • Capsule(s) administered orally once daily

    Also known as: MBX-8025, Livdelzi®

  • DrugPlacebo to match Seladelpar

    Capsule(s) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Relative Change in Baseline Serum Alkaline Phosphatase (AP) at Week 24

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were planned to be collected up to 24 weeks. Due to the early study termination, data is reported up to Day 59.

    Time frame: Up to Day 59

  2. Incidence of Primary Sclerosing Cholangitis (PSC)-Related Symptoms or Procedures

    Time frame: Up to 24 weeks

  3. Incidence of Hepatic Disease Progression Events

    Hepatic disease progression events is defined by the first occurrence of the following events: liver transplantation, Model for End-Stage Liver Disease (MELD) score ≥ 15, hepatic decompensation events, and hepatocellular carcinoma.

    Time frame: Up to 24 weeks

07

Results

Posted Jan 16, 2025
Limitations and caveats
The study was terminated early and only 1 participant enrolled in the placebo arm and received placebo up to Day 14. The pre-specified analyses were not conducted due to study termination.

Participant flow

Study was to be conducted in 60 sites in Australia, Europe, Israel, and North America. Only 1 site in the United States enrolled. The study was terminated early and only 1 participant was enrolled in the placebo arm.

Participant flow — Overall Study
MilestonePlacebo
Started1
Completed0
Not completed1
Withdrew: Study terminated by sponsor1

Outcome measures

PrimaryRelative Change in Baseline Serum Alkaline Phosphatase (AP) at Week 24
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were planned to be collected up to 24 weeks. Due to the early study termination, data is reported up to Day 59.

Time frame:
Up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlacebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)0
SecondaryIncidence of Primary Sclerosing Cholangitis (PSC)-Related Symptoms or Procedures
Time frame:
Up to 24 weeks

No measurements were reported for this outcome.

SecondaryIncidence of Hepatic Disease Progression Events

Hepatic disease progression events is defined by the first occurrence of the following events: liver transplantation, Model for End-Stage Liver Disease (MELD) score ≥ 15, hepatic decompensation events, and hepatocellular carcinoma.

Time frame:
Up to 24 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Up to Day 59. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Placebo
65 to 84 years1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo
Female0
Male1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Placebo
Region of Enrollment
Region of Enrollment(Participants)Placebo
United States1
08

Study locations

10 sites
  • Sutter Pacific Medical Foundation - California Pacific Medical Center
    San Francisco, California 94109, United States
  • University of Colorado Denver and Hospital
    Aurora, Colorado 80045, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • New York University
    New York, New York 10016, United States
  • Liver Institute of Virginia
    Newport News, Virginia 23602, United States
  • Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • Toronto Centre for Liver Disease-Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • ID Clinic
    Mysłowice, 41-400, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jan 2020, 1 month.

Results were first posted in Jan 2025, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2019
First posted
Jul 18, 2019
StartActual
Nov 12, 2019
Primary completionActual
Jan 9, 2020
CompletionActual
Jan 9, 2020
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04024813
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Nov 12, 2019
Primary completion
Jan 9, 2020
Completion
Jan 9, 2020
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion